C. L. Sawyers, C. Abate-shen, and K. C. Anderson, AACR cancer progress report 2013, Clin Cancer Res, vol.19, pp.4-98, 2013.

A. Sangiovanni and M. Colombo, Treatment of hepatocellular carcinoma: Beyond international guidelines, Liver Int, vol.36, issue.1, pp.124-133, 2016.

M. Ringelhan, D. Pfister, O. Connor, and T. , The immunology of hepatocellular carcinoma, Nat Immunol, vol.19, pp.222-254, 2018.

C. L. Elsegood, J. E. Tirnitz-parker, and J. K. Olynyk, Immune checkpoint inhibition: Prospects for prevention and therapy of hepatocellular carcinoma, Clin Transl Immunol, vol.6, p.161, 2017.

G. S. Roth and T. Decaens, Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives, Eur J Cancer, vol.87, pp.101-113, 2017.

M. Ramzan, N. Sturm, and T. Decaens, Liver-infiltrating CD8(1) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma, Liver Int, vol.36, pp.434-478, 2016.

B. J. Wang, J. J. Bao, and J. Z. Wang, Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma, World J Gastroenterol, vol.17, pp.3322-3331, 2011.

F. Shi, M. Shi, and Z. Zeng, PD-1 and PD-L1 upregulation promotes CD8(1) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients, Int J Cancer, vol.128, pp.887-96, 2011.

Q. Gao, X. Y. Wang, and S. J. Qiu, Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma, Clin Cancer Res, vol.15, pp.971-980, 2009.

J. Calderaro, B. Rousseau, and G. Amaddeo, Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features, Hepatology, vol.64, pp.2038-2084, 2016.

A. B. El-khoueiry, B. Sangro, and T. Yau, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, vol.389, pp.2492-502, 2017.

A. X. Zhu, R. S. Finn, and J. Edeline, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial, Lancet Oncol, vol.19, pp.940-52, 2018.

G. Zhou, D. Sprengers, and P. Boor, Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas, Gastroenterology, vol.153, pp.1107-1126, 2017.

E. Jouvin-marche, M. Jilkova, Z. Thelu, and M. A. , Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels, J Infect Dis, vol.209, pp.1907-1922, 2014.

M. Jilkova, Z. Decaens, T. Marlu, and A. , Sex differences in spontaneous degranulation activity of intrahepatic natural killer cells during chronic hepatitis B: Association with estradiol levels, Mediators Inflamm, p.3214917, 2017.

M. Jilkova, Z. Afzal, S. Marche, and H. , Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(1) neutrophils, Liver Int, vol.36, pp.1116-1140, 2016.

A. I. Daud, K. Loo, and M. L. Pauli, Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma, J Clin Invest, vol.126, pp.3447-52, 2016.

D. S. Thommen, V. H. Koelzer, and P. Herzig, A transcriptionally and functionally distinct PD-1(1) CD8(1) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade, Nat Med, vol.24, pp.994-1004, 2018.

S. Han, C. Zhang, and Q. Li, Tumour-infiltrating CD4(1) and CD8(1) lymphocytes as predictors of clinical outcome in glioma, Br J Cancer, vol.110, pp.2560-2568, 2014.

S. Simon and N. Labarriere, PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?, Oncoimmunology, vol.7, p.1364828, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01592666

A. Gabrielson, Y. Wu, and H. Wang, Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC, Cancer Immunol Res, vol.4, pp.419-449, 2016.

F. Foerster, M. Hess, and A. Gerhold-ay, The immune contexture of hepatocellular carcinoma predicts clinical outcome, Sci Rep, vol.8, p.5351, 2018.

Y. Huang, C. Ma, and Q. Zhang, CD41 and CD81 T cells have opposing roles in breast cancer progression and outcome, Oncotarget, vol.6, pp.17462-78, 2015.

Q. Gao, S. J. Qiu, and J. Fan, Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection, J Clin Oncol, vol.25, pp.2586-93, 2007.

T. Flecken, N. Schmidt, and S. Hild, Immunodominance and functional alterations of tumor-associated antigen-specific CD81 T-cell responses in hepatocellular carcinoma, Hepatology, vol.59, pp.1415-1441, 2014.

W. Yao, J. C. He, and Y. Yang, The prognostic value of tumorinfiltrating lymphocytes in hepatocellular carcinoma: A systematic review and meta-analysis, Sci Rep, vol.7, p.7525, 2017.

K. J. Chen, S. Z. Lin, and L. Zhou, Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis, PLoS One, vol.6, p.24671, 2011.

C. Zheng, L. Zheng, and J. K. Yoo, Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing, Cell, vol.169, pp.1342-56, 2017.

V. Chew, L. Lai, and L. Pan, Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses, Proc Natl Acad Sci, vol.114, pp.5900-5909, 2017.

J. Chen, J. T. Zhao, and J. , Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint, Oncotarget, vol.7, pp.41274-84, 2016.

S. G. Kalathil, A. A. Lugade, and A. Miller, PD-11 and Foxp31 T cell reduction correlates with survival of HCC patients after sorafenib therapy, JCI Insight, vol.1, p.86182, 2016.

H. D. Kim, G. W. Song, and S. Park, Association between expression level of PD1 by tumor-infiltrating CD8(1) T cells and features of hepatocellular carcinoma, Gastroenterology, vol.155, pp.1936-50, 2018.

S. Koyama, E. A. Akbay, and Y. Y. Li, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat Commun, vol.7, p.10501, 2016.

R. Y. Huang, A. Francois, and A. R. Mcgray, Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer, Oncoimmunology, vol.6, p.1249561, 2017.

Y. Lan, D. Zhang, and C. Xu, Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta, Sci Transl Med, vol.10, p.5488, 2018.

D. S. Thommen, J. Schreiner, and P. Muller, Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors, Cancer Immunol Res, vol.3, pp.1344-55, 2015.

L. S. Walker and D. M. Sansom, Confusing signals: Recent progress in CTLA-4 biology, Trends Immunol, vol.36, pp.63-70, 2015.

X. Xiao, W. Gong, and G. Demirci, New insights on OX40 in the control of T cell immunity and immune tolerance in vivo, J Immunol, vol.188, pp.892-901, 2012.

K. Xie, L. Xu, and H. Wu, OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis, Oncoimmunology, vol.7, p.1404214, 2018.

N. H. Segal, A. R. He, and T. Doi, Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer, Clin Cancer Res, vol.24, pp.1816-1839, 2018.

, Open Access This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal